Yichang, China

Dali Liang

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Yichang Humanwell Pharmaceuticals Co., Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dali Liang - Innovator in Medical Treatments

Introduction

Dali Liang is a prominent inventor based in Yichang, China. She has made significant contributions to the field of medical treatments through her innovative research and development. Her work focuses on the creation of compounds that can aid in the treatment of various medical disorders.

Latest Patents

Dali Liang holds a patent for "Peptides for treatment of medical disorders." This invention provides compounds that act as selective kappa-opioid receptor agonists. The patent details the method of preparation for these compounds, the compositions that include them, and the methods for treating medical disorders related to kappa-opioid receptor agonists. She has 1 patent to her name, showcasing her dedication to advancing medical science.

Career Highlights

Dali Liang is associated with Yichang Humanwell Pharmaceuticals Co., Ltd., where she applies her expertise in pharmaceutical development. Her role in the company allows her to collaborate with other talented professionals in the industry, further enhancing her contributions to medical innovation.

Collaborations

Some of her notable coworkers include Subo Liao and Jun Yang. Their collaboration fosters a dynamic environment for research and development, leading to groundbreaking advancements in medical treatments.

Conclusion

Dali Liang's work exemplifies the impact of innovation in the medical field. Her contributions through her patent and collaboration with esteemed colleagues highlight her commitment to improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…